{
    "title": "112_hr6446",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Improving Diagnostic Innovations Act \nof 2012''.\n\nSEC. 2. CREATING INCENTIVES FOR INNOVATIVE DIAGNOSTICS.\n\n    (a) Improvements to Process for Determining Fee Schedule Amounts \nfor New Tests.--\n            (1) Clarifying factors for rate-setting.--\n                    (A) In general.--In determining the payment amount \n                under gapfilling procedures (as described in section \n                414.508(b) of title 42, Code of Federal Regulations, or \n                any successor regulation to such section) for new \n                clinical diagnostic laboratory tests under section \n                1833(h)(8) of the Social Security Act (42 U.S.C. \n                1395l(h)(8)), the Secretary of Health and Human \n                Services (in this section referred to as the \n                ``Secretary'') shall take into account, as applicable \n                and available, the following factors with respect to \n                such a new test:\n                            (i) Impact on patient care.--The impact of \n                        the new test on patient care, patient \n                        management, or patient treatment.\n                            (ii) Technical characteristics.--The \n                        technical characteristics of the new test, and \n                        the resources required to develop, validate, \n                        and perform the new test.\n                            (iii) Claims data.--Data from claims for \n                        which payment is made under part B of title \n                        XVIII of the Social Security Act.\n                            (iv) Laboratory charges.--Amounts charged \n                        by laboratories to self-pay patients for the \n                        new test.\n                            (v) Private insurance rates.--Amounts paid \n                        to laboratories for such new test under private \n                        health insurance coverage offered in the group \n                        market and the individual market.\n                            (vi) Advisory panel recommendations.--The \n                        findings and recommendations of the independent \n                        advisory panel convened under paragraph (2) \n                        with respect to that new test and any comments \n                        received during the open meeting of the \n                        advisory panel.\n                            (vii) Additional factors.--Such other \n                        factors as the Secretary may specify.\n            (2) Input from patients, clinicians, and technical \n        experts.--\n                    (A) Requirement for independent advisory panel.--\n                The Secretary shall convene an independent advisory \n                panel from which the Secretary shall request \n                information and recommendations regarding any new test \n                (as referred to under subparagraph (A) of section \n                1833(h)(8) of the Social Security Act (42 U.S.C. \n                1395l(h)(8))) for which payment is made under such \n                section, including technical, clinical, and quality \n                information.\n                    (B) Composition of independent advisory panel.--The \n                independent advisory panel shall be comprised of 19 \n                members, including--\n                            (i) 4 individuals with expertise and \n                        experience with advanced clinical diagnostic \n                        laboratory tests, including expertise in the \n                        technical characteristics of the new test;\n                            (ii) 3 representatives of patients, \n                        including a patient representative for rare \n                        disorders;\n                            (iii) 3 clinicians who use results of the \n                        new test in patient care;\n                            (iv) 3 individuals with expertise in the \n                        requirements to develop, validate, and perform \n                        the new test;\n                            (v) 2 laboratorians;\n                            (vi) 2 experts in the area of \n                        pharmacoeconomics or health technology \n                        assessment; and\n                            (vii) 2 individuals with expertise on the \n                        impact of new tests on quality of patient care, \n                        including genetic counselors.\n                    (C) Terms.--A member of the panel shall be \n                appointed to serve a term of 6 years, except with \n                respect to the members first appointed, whose terms of \n                appointment shall be staggered evenly over 2-year \n                increments.\n                    (D) Expert consultants.--The Secretary may include \n                to serve temporarily on the panel individuals who have \n                expertise pertaining to the new test involved.\n                    (E) Open meetings.--The Secretary shall receive or \n                review the findings and recommendations of the \n                independent advisory panel with respect to the new \n                tests described in subparagraph (A) involved during a \n                meeting open to the public and provide opportunity for \n                public comment.\n                    (F) Clarification of authority of secretary to \n                consult carriers.--Nothing in this section shall be \n                construed as affecting the authority of the Secretary \n                to consult with appropriate Medicare administrative \n                contractors.\n    (b) Process for Assignment of Temporary Codes for Diagnostic \nTests.--The Secretary shall establish a process for application for the \nassignment of a temporary national HCPCS code to uniquely identify a \ndiagnostic test until a permanent national HCPCS code is available for \nassignment to that test. Assignments of a temporary national HCPCS code \nshall occur on a quarterly basis. The Secretary shall provide public \nnotice through the Centers for Medicare & Medicaid Services Web site of \napplications made for such temporary national HCPCS codes. Upon \nassignment of a temporary code under this process, the Secretary shall \ntreat such test as a new test for purposes of section 1833(h)(8) of the \nSocial Security Act.\n    (c) Development of Further Improvements in Rate-Setting \nProcesses.--The Secretary shall analyze the process used for the \ngapfilling procedure used in determining payment amounts for new \nclinical diagnostic laboratory tests under section 1833(h)(8) of the \nSocial Security Act. Taking into account the changes made by this \nsection, the Secretary shall identify further changes to improve the \naccuracy and appropriateness of resulting rates and the openness, \ntransparency, and predictability of the process. The Secretary shall \nexamine what and how many entities should perform gapfilling, under \ncontract or otherwise, and how to ensure that the process is informed \nby appropriate expertise and proceeds in a transparent and accountable \nmanner. The Secretary shall implement improvements in the process, \ninsofar as these are possible under the law through regulations, after \npublic notice and opportunity for comment. For changes the Secretary \ndetermines would require a change in law, the Secretary shall transmit \nrecommendations to the Speaker of the House and the President of the \nSenate not later than July 1, 2013.\n    (d) Definitions.--For purposes of this section:\n            (1) New clinical diagnostic laboratory tests.--The term \n        ``new clinical diagnostic laboratory test'' means a clinical \n        diagnostic laboratory test--\n                    (A) that is assigned a new or substantially revised \n                code on or after January 1, 2013; or\n                    (B) for which an application for a temporary \n                national HCPCS code is made under subsection (b) on or \n                after January 1, 2013.\n            (2) Self-pay patient.--The term ``self-pay patient'' means, \n        with respect to a health care item or service, an individual \n        who pays out of pocket for such item or service and who does \n        not have health insurance coverage for such item or service.\n    (e) Effective Date.--This section shall take effect on the date of \nenactment of this Act, and shall apply with respect to new clinical \ndiagnostic laboratory tests."
}